FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1036-1037 September 26, 2002 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Freebairn, R. Related Article by Bernard, G. R. PubMed Citation

To the Editor: In their report on the efficacy of activated protein C in reducing mortality from sepsis at 28 days (March 8, 2001, issue),¹ Bernard et al. presented the results of a retrospective subgroup analysis, which showed that the administration of low-dose heparin, in addition to activated protein C, had no effect on safety.¹ Heparin and low-molecular-weight heparin are anticoagulants with antiinflammatory properties.² Heparin is recommended for prophylaxis against thromboembolism in patients with sepsis.³ We conducted a study to determine whether the administration of heparin affected efficacy, hypothesizing that the use of low-dose (or low-molecular-weight) heparin would improve survival . . . [Full Text of this Article]

This article has been cited by other articles:

• Hayashida, K., Parks, W. C., Park, P. W. (2009). Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines. Blood 114: 3033-3043 [Abstract] [Full Text]  
• Hayashida, K., Chen, Y., Bartlett, A. H., Park, P. W. (2008). Syndecan-1 Is an in Vivo Suppressor of Gram-positive Toxic Shock. J. Biol. Chem. 283: 19895-19903 [Abstract] [Full Text]  
• Levi, M., Levy, M., Williams, M. D., Douglas, I., Artigas, A., Antonelli, M., Wyncoll, D., Janes, J., Booth, F. V., Wang, D., Sundin, D. P., Macias, W. L., for the Xigris and Prophylactic HepaRin Evaluation, (2007). Prophylactic Heparin in Patients with Severe Sepsis Treated with Drotrecogin Alfa (Activated). Am. J. Respir. Crit. Care Med. 176: 483-490 [Abstract] [Full Text]  
• Cepkova, M., Matthay, M. A. (2006). Pharmacotherapy of Acute Lung Injury and the Acute Respiratory Distress Syndrome. J Intensive Care Med 21: 119-143 [Abstract]  
• Kent, D. M., Fendrick, A. M., Langa, K. M. (2004). New and Dis-Improved: On the Evaluation and Use of Less Effective, Less Expensive Medical Interventions. Med Decis Making 24: 281-286 [Abstract]  
• Freebairn, R., Ramsay, S., Gomersall, C., Davidson, B. L., Geerts, W. H., Lensing, A. W.A. (2003). Low-Dose Heparin for Severe Sepsis. NEJM 348: 1185-1186 [Full Text]